Acquired immune-mediated TTP after ivonescimab chemoimmunotherapy with cholestatic liver injury an

Overview of available source and article title

The only accessible information from the supplied Frontiers in Immunology page is the article title and site navigation elements. The title indicates a case report and literature review concerning acquired immune-mediated thrombotic thrombocytopenic purpura following ivonescimab-containing chemoimmunotherapy, associated with severe cholestatic liver injury and reversible acute kidney injury. No article text or substantive body content from the case report or review was present in the provided source material.

Reported clinical syndrome and complications in title

The article title explicitly names the principal clinical entities reported: acquired immune-mediated thrombotic thrombocytopenic purpura (TTP), severe cholestatic liver injury, and reversible acute kidney injury (AKI). The title also identifies the exposure temporally associated with the event as ivonescimab-containing chemoimmunotherapy. Beyond the title, the supplied content contains only site and journal navigation data; no case narrative, clinical timeline, or diagnostic confirmation details were available.

Missing patient- and case-specific details

The supplied source did not include any patient demographics, medical history, or specifics about the cancer diagnosis prompting chemoimmunotherapy. The following key case elements were not reported in the provided text and therefore cannot be summarized:

• Patient age, sex, relevant comorbidities, or baseline organ function.
• Indication for chemoimmunotherapy and regimen composition aside from the title’s mention of ivonescimab.
• Timing of symptom onset relative to drug exposure or chemo cycles.

Missing diagnostic and laboratory data

No laboratory, imaging, or pathology data were contained in the available source material. The following diagnostic information that would normally be necessary to confirm and characterize TTP and organ injury was not provided:

• Hematologic indices (platelet counts, hemolysis markers, schistocyte report).
• ADAMTS13 activity and inhibitor testing or levels.
• Liver function tests characterizing cholestatic pattern (bilirubin fractions, alkaline phosphatase, gamma-GT) or imaging/biopsy findings.
• Renal function metrics (creatinine, urine studies) and assessment indicating reversibility.
• Microbiologic or other studies excluding alternative causes.

Because these data were not present in the supplied content, no conclusions about diagnostic certainty, severity grading, or mechanisms can be drawn from the source text.

Missing management, treatment, and outcome information

The source did not report therapeutic measures, timing of interventions, or the patient’s clinical course. Specifically, no information was available on:

• Immediate management of suspected TTP (for example, plasma exchange, corticosteroids, caplacizumab, rituximab) or whether those were used.
• Modifications to cancer therapy or discontinuation of ivonescimab.
• Supportive measures for cholestatic liver injury or AKI, need for dialysis, or hepatology/nephrology consultations.
• Duration of hospitalization, complications, or long-term follow-up beyond the title’s note that AKI was reversible.

Because treatment and outcome details were not included in the provided page content, they cannot be restated or interpreted here.

Literature review and contextual details not provided

The article title indicates a literature review accompanies the case report. However, the supplied source text did not include the review content, references, or discussion points. Therefore, the following are not available from the provided material:

• How this case compares with prior reports linking ivonescimab or other agents to immune-mediated TTP.
• Proposed pathophysiologic mechanisms discussed by the authors.
• Incidence estimates, risk factors, or guidance drawn from the literature review.

Limitations due to source content and implications for readers

The available Frontiers page content consisted of journal navigation and structural site elements rather than the article manuscript. As a result:

• No new clinical data from the reported case can be reliably extracted or summarized.
• Any clinical interpretation, management guidance, or evidence synthesis beyond the article title would be speculative and is omitted here in adherence to source-only reporting.
• Readers seeking the full case details, diagnostic data, management steps, and literature synthesis should consult the complete article on the journal website or contact the authors/publisher for the full text.

Conclusions and recommended next steps for readers

The supplied source confirms the existence of a published case report titled to indicate an association between ivonescimab-containing chemoimmunotherapy and acquired immune-mediated TTP with severe cholestatic liver injury and reversible AKI. However, the body of the article and the literature review content were not included in the provided material; critical clinical details, diagnostic results, management strategies, and outcomes were therefore not reported here.

For clinicians and readers who need the complete case and review findings, the next step is to access the full Frontiers in Immunology article (via the journal site or DOI) to review the patient data, diagnostic criteria, therapeutic interventions, and authors’ discussion and conclusions.